
Alumis Inc (ALMS) Stock Forecast & Price Target
Alumis Inc (ALMS) Analyst Ratings
Bulls say
Alumis is a promising investment opportunity with a strong pipeline and potential catalysts in the upcoming months, including 2-year safety data for their lead drug envudeucitinib in Phase II PsO trials and an NDA submission for envudeucitinib in PsO in 4Q26. The company also has a diversified pipeline, including A-005, a brain-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases, and a new clinical candidate in Phase I trials. The company's valuation is fair, with a 12-month price objective of $25 based on a discounted cash flow model, but risks such as potential delays and competition in the market should be considered.
Bears say
Alumis is a clinical-stage biopharmaceutical company with a focus on developing two TYK2 inhibitors for the treatment of Psoriasis andSLE. While the company's Phase IIb study missed both primary and secondary endpoints in the overall population, the higher-than-expected placebo response in the IFNGS-low subgroup and the lower proportion of SLE patients with severe disease could have influenced the results. The company also faces competition in the market from both in-class therapies and other therapeutic modalities, and may need additional financing before reaching profitability.
This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.
Alumis Inc (ALMS) Analyst Forecast & Price Prediction
Start investing in Alumis Inc (ALMS)
Order type
Buy in
Order amount
Est. shares
0 shares